Education
About Us
Working with TipRanks
Follow Us
Tryptamine Therapeutics Limited (AU:ENP)
ASX:ENP
ENP Stock Chart & Stats
AU$0.03
<AU$0.01(3.33%)
―
--
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.05
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.64M
Market Cap
AU$48.42M
Enterprise ValueAU$46.93M
Total Cash (Recent Filing)AU$3.03M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.94
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,613,941,200
10 Day Avg. Volume1,728,571
30 Day Avg. Volume1,638,927
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)8.55
Price to Sales (P/S)0.00
P/FCF Ratio-6.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt materially reduces financial distress risk for a pre-revenue biotech. This structural strength preserves strategic optionality to fund clinical programs, negotiate partnerships, or raise capital without immediate solvency pressure, supporting multi‑quarter execution.
Positive Shareholders' EquityHaving ~ $6.0M of equity provides a measurable cushion against ongoing losses and supports near‑term operations. For a clinical-stage developer, positive equity improves balance sheet credibility and can help secure partner deals or less dilutive financing terms over the next several quarters.
Focused IP And Clinical StrategyA clear, specialized focus on psilocybin-based therapeutics and building intellectual property creates a durable strategic position. If clinical progress translates to differentiated assets, the company can capture niche regulatory or licensing opportunities in a structurally growing psychedelics R&D sector.
Bears Say
No Commercial RevenueZero revenue across consecutive years means the business is fully reliant on development milestones and external funding to survive. Without commercialized products, durability of operations depends on successful trials or partnerships, delaying sustainable margins and cash generation.
Heavy Operating Cash BurnSustained negative operating and free cash flow drives persistent funding requirements. Over a multi‑quarter horizon this raises dilution and execution risk: trial timelines or IP development could be interrupted if fresh capital or strategic partnerships are not secured on acceptable terms.
Persistent Losses And Negative ROEA large negative ROE and recurring net losses indicate shareholder capital is being consumed to fund R&D. Over time this erodes investor value and compels frequent capital raises, which can dilute equity and limit the company's ability to sustain long‑range development without clear clinical success.
Tryptamine Therapeutics News
ENP FAQ
What was Tryptamine Therapeutics Limited’s price range in the past 12 months?
Tryptamine Therapeutics Limited lowest share price was AU$0.03 and its highest was AU$0.05 in the past 12 months.
What is Tryptamine Therapeutics Limited’s market cap?
Tryptamine Therapeutics Limited’s market cap is AU$48.42M.
When is Tryptamine Therapeutics Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Tryptamine Therapeutics Limited’s earnings last quarter?
Currently, no data Available
Is Tryptamine Therapeutics Limited overvalued?
According to Wall Street analysts Tryptamine Therapeutics Limited’s price is currently Undervalued.
Does Tryptamine Therapeutics Limited pay dividends?
Tryptamine Therapeutics Limited does not currently pay dividends.
What is Tryptamine Therapeutics Limited’s EPS estimate?
Tryptamine Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tryptamine Therapeutics Limited have?
Tryptamine Therapeutics Limited has 1,613,941,200 shares outstanding.
What happened to Tryptamine Therapeutics Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tryptamine Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:ENP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tryptamine Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:ENP Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$30.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.21%
12-Months-Change
Fundamentals
Return on Equity
-94.13%
Trailing 12-Months
Asset Growth
-8.94%
Trailing 12-Months
Company Description
Tryptamine Therapeutics Limited
Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the development of TRP-8802, a synthetic and oral psilocybin currently under phase 2a clinical trial for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia and irritable bowel syndrome. The company was formerly known as Tryptamine Therapeutics Limited and changed its name to Entropy Neurodynamics Limited in November 2025. Entropy Neurodynamics Limited was founded in 2019 and is based in Camberwell, Australia.